\u2022 Based on the 2026 ASCO Annual Meeting held in Chicago, USA.<\/p>\n
A simplified summary for patients from the world's largest cancer congress.<\/p>\n
Every year in May\u2013June, cancer specialists from all over the world gather. ASCO Annual Meeting<\/strong>\u2018They come together in 2026. This meeting is where the most important innovations in cancer treatment are announced for the first time. Over 40,000 experts<\/strong> participated. Below, we have summarized the most noteworthy and promising results for patients in language that can be understood by those without medical training.<\/p>\n<\/div>\n Pancreatic cancer is one of the most difficult cancers to treat, and for years there had been no significant progress in this area. Therefore... daraxonrasib<\/strong> The results of a new drug called [drug name] were the most talked-about news at the meeting. This drug targets what causes cancer cells to grow. RAS<\/em> targeting a protein called, an oral pill<\/strong>truck.<\/p>\n In the RASolute 302 study, the drug also produced fewer serious side effects compared to chemotherapy.<\/p>\n For this type of cancer, where options have been very limited for many years, a new treatment that offers both longer survival and better quality of life, and can be taken as a pill instead of an injection, is on the horizon. The drug's approval process has begun.<\/p>\n<\/div>\n<\/div>\n<\/div>\n In high-risk but not yet metastatic prostate cancer, patients usually undergo surgery; however, in about half of them, the cancer returns over time. PROTEUS study<\/strong>, hormone therapy before and after surgery apalutamide<\/strong> They examined the results of adding a pill called [name of pill].<\/p>\n In early-stage, high-risk prostate cancer, supplementing surgery with potent medication may delay disease recurrence. This approach is considered to have the potential to change a treatment philosophy that has remained unchanged for decades.<\/p>\n<\/div>\n<\/div>\n<\/div>\n In a small percentage of bowel cancers BRAF V600E<\/em> They have a genetic mutation called [name of mutation], and the course of the disease is generally more difficult for these patients. BREAKWATER study<\/strong>, standard chemotherapy encorafenib + cetuximab<\/strong> They tested the addition of targeted drugs called [name of drug].<\/p>\n The risk of death was reduced by approximately half; the rate at which the tumor shrank also increased significantly.<\/p>\n Knowing the gene alterations in a patient's tumor allows for the selection of personalized and much more effective treatments. This, \u201c"Personalized cancer treatment"\u201d<\/strong> It is a fine example of understanding.<\/p>\n<\/div>\n<\/div>\n<\/div>\n In the HORIZON-CRC01 study<\/strong>, HER2<\/em> in patients who carry this protein and do not respond to standard treatments trastuzumab rezetekan<\/strong> This antibody-drug combination significantly delayed disease progression compared to standard treatment.<\/p>\n Targeted therapies deliver chemotherapy directly into cancer cells, causing less damage to healthy tissues. Drugs in this class are proving effective against an increasing number of cancer types.<\/p>\n<\/div>\n<\/div>\n<\/div>\n Some types of lung cancer REJECTION<\/em> It carries a gene mutation called [name]. In the study LIBRETTO-432<\/strong>, to these patients who have undergone surgery selperkatinib<\/strong> Administering this pill reduces the risk of cancer returning or death. %83 oran\u0131nda<\/strong> reduced.<\/p>\n Using targeted medication along with surgery in the early stages can significantly prevent cancer recurrence. Furthermore, new and effective pill options have been developed for lung cancer patients carrying rare genetic mutations.<\/p>\n<\/div>\n<\/div>\n<\/div>\n Victoria-1 study<\/strong>, hormone positive \/ HER2 negative and PIK3CA<\/em> in breast cancer patients carrying the genetic alteration and who have shown progression in previous treatment gedatolisib<\/strong> They evaluated combining a new drug called [drug name] with hormone therapy and obtained promising results.<\/p>\n Additionally, a new targeted therapy drug for triple-negative breast cancer has been reported to both slow disease progression and extend survival.<\/p>\n Breast cancer is not a single disease; treatments are increasingly being selected with greater precision for different subtypes, and the options are expanding.<\/p>\n<\/div>\n<\/div>\n<\/div>\n Immunotherapy is a treatment approach that strengthens the body's immune system to fight cancer. Key developments this year include:<\/p>\n Immunotherapy treatments are no longer limited to just a few types of cancer; they are reaching more and more patients and can provide very long-term control in some cases.<\/p>\n<\/div>\n<\/div>\n<\/div>\n This year's meeting focused not only on new drugs, but also on simple and low-cost methods that improve patients' quality of life before chemotherapy. dietary regulations<\/strong> And yoga<\/strong> Data was shared indicating that movement-based activities like these are beneficial to patients. Additionally, some medications used in the treatment of diabetes and weight loss (GLP-1 group<\/strong>The potential benefits for cancer patients were discussed.<\/p>\n Good cancer care is not just about treating the tumor, but also about making the patient feel good. Sometimes the most valuable improvements come through the simplest methods.<\/p>\n<\/div>\n<\/div>\n<\/div>\n <\/p>\n <\/p>\n <\/p>\n <\/p>\n Important Note:<\/strong> This article is for general informational purposes only and does not constitute personal medical advice. Some of the treatments mentioned here are still under investigation or may not be suitable in all countries\/for all patients. Each patient's situation is unique. Decisions regarding your treatment should only be made in consultation with your attending physician.<\/p>\n Preparer: Tansan Clinic<\/strong> \u2022 June 2026<\/p>\n<\/div>\n<\/div>","protected":false},"excerpt":{"rendered":" \u2022 Based on the 2026 ASCO Annual Meeting held in Chicago, USA \u2022 A concise summary for patients from the world's largest cancer congress Tansan Clinic June 2026 450+ scientific studies Every year in May\u2013June, cancer experts from around the world gather at the ASCO Annual Meeting. This meeting is where the most important innovations in cancer treatment are announced for the first time.<\/p>","protected":false},"author":2,"featured_media":2626,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[524],"tags":[],"class_list":["post-3495","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-haberler"],"yoast_head":"\nPancreatic Cancer<\/span> \u2014 It almost doubled life expectancy.<\/h2>\n<\/div>\n
Prostate Cancer <\/span>\u2014 Surgery reduced the risk of spread.<\/h2>\n<\/div>\n
Bowel Cancer \u00b7 BRAF<\/span> \u2014 Life expectancy has doubled.<\/h2>\n<\/div>\n
Colon Cancer <\/span>Next-generation targeted therapy for HER2-positive patients<\/h2>\n<\/div>\n
Lung Cancer \u2013 <\/span>Ameliyat sonras\u0131 n\u00fcks riskini %83 azaltt\u0131<\/h2>\n<\/div>\n
\u00a0Breast Cancer \u2014 New combination for patients carrying the PIK3CA gene alteration.<\/h2>\n
Immunotherapy <\/span>\u2014 Treatments that utilize the body's own defenses are expanding.<\/h2>\n<\/div>\n
\n
Supportive Care <\/span>\u2014 Low-cost, simple approaches have also come to the forefront.<\/h2>\n<\/div>\n
Key Points to Remember<\/h3>\n
\n